SkyQuest Technology Group recently introduced Influenza Diagnostics Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Influenza Diagnostics Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Influenza Diagnostics Market size was valued at USD 1.1 Billion in 2023 and is poised to grow from USD 1.14 Billion in 2024 to USD 1.51 Billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).
Increasing healthcare expenditure and the availability of effective treatment options have led to an increase in the median age worldwide. The WHO, CDC, and European Centre for Disease Prevention and Control, among other regulatory bodies, are actively recording incidence & prevalence data to counter the disease systematically. These bodies work together with local governments to achieve overall control of the treatment and management of this disease. The Global Influenza Program (GIP) is one initiative the WHO undertook to provide technical support, strategic guidance, and coordination activities concerning zoonotic, pandemic, and seasonal flu cases. Such initiatives are expected to boost Influenza Diagnostics market growth during the forecast period.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/influenza-diagnostics-market
The 2025 global Influenza Diagnostics Market report provides a comprehensive analysis of key industry players, market trends, pricing structures, and competitive dynamics, offering insights into the market landscape from 2025 to 2032. As a rapidly evolving sector, the Influenza Diagnostics Market drives economic growth, innovation, and technological advancements through the development, production, and distribution of products and services. This report highlights the market’s growth potential and its impact on global industries, providing valuable insights for stakeholders, investors, and policymakers.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Influenza Diagnostics Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Product
Test kit and Reagents, Instruments, Others
Test
Molecular Diagnostic Test (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification, Tests), Transcription Mediated Amplification Based Assay, Loop Mediated Isothermal Amplification Based Assay, Nucleic Acid Sequence based Amplification Tests, Traditional Diagnostics Tests (Rapid Influenza Diagnostic Test, Viral Culture Test, Direct Fluorescent Antibody Test, Serological Tests)
End User
Diagnostic Laboratories, Hospitals and Clinics, Others
Influenza Diagnostics Market – Regional Analysis:
– Influenza Diagnostics North America Market includes (Canada, Mexico, USA)
– Influenza Diagnostics Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Influenza Diagnostics Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Influenza Diagnostics South America Market includes (Brazil, Argentina)
– Influenza Diagnostics Oceania Market (Australia & New Zealand)
Top Market Players in Influenza Diagnostics Market are:
Thermo Fisher Scientific (US)
Becton, Dickinson and Company (US)
F. Hoffmann-La Roche AG (Switzerland)
Hologic, Inc. (US)
Abbott Laboratories, Inc. (US)
DiaSorin (Italy)
QIAGEN N.V. (Netherlands)
Fujirebio Diagnostics, Inc. (Japan)
Meridian Bioscience, Inc. (US)
Luminex Corporation (US)
Seegene Inc. (South Korea)
Bio-Rad Laboratories, Inc. (US)
Alere Inc. (US)
GenMark Diagnostics, Inc. (US)
Roche Diagnostics (Switzerland)
BioMérieux SA (France)
Cepheid (US)
SD Biosensor (South Korea)
Acon Laboratories, Inc. (US)
Inverness Medical Innovations, Inc. (US)
Influenza Diagnostics Market Recent Developments:
Becton, Dickinson and Company got the U.S. FDA clearance for a respiratory viral panel in August 2023 for the identification of patients infected by flue and respiratory syncytial virus.
Lucira COVID-19 & Flu Home Test, developed by Pfizer Inc. was cleared in February 2023 by the U.S. FDA emergency use of authorization approval to diagnose influenza viruses A and B. The test is an over the counter at-home diagnostic test.
In October 2022, the European and North American regulatory bodies provided Hologic Inc. approval ti launch its Aptima SARS-CoV-2/Flue test.
Also Read –
https://www.openpr.com/news/3955664/us-laundry-facilities-and-dry-cleaning-services-market
https://pando.life/article/892056
Forward-Looking Insights
The Influenza Diagnostics Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
